Sein métastatique RH+
SAFIR-TOR
Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women.
Paris, Saint-Cloud
PAUL-HENRI COTTU
Sein métastatique triple négatif
CO40151
A phase ib, open-label, multicenter study evaluating the safety and efficacy of ipatasertib in combination with atezolizumab and paclitaxel or nab-paclitaxel in patients with locally advanced or metastatic triple- negative breast cancer
Paris
VADS
CA209-9T9 ProNiHN
A FRENCH, PROSPECTIVE, NON-INTERVENTIONAL RESEARCH (NIR) OF NIVOLUMAB IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) PROGRESSING ON OR AFTER PLATINUM-BASED THERAPY
Paris
CHRISTOPHE LE TOURNEAU
Pédiatrie Tumeurs solides
I3Y-MC-JPCS
JPCS(2.1) Clinical Protocol Addendum Page 1;LY2835219;1. Protocol Addendum I3Y-MC-JPCS(2.1);A Phase 1b Dose Escalation Study of Abemaciclib in;Combination with Temozolomide and Irinotecan (Part A);and Abemaciclib in Combination with Temozolomide;(Part B) in Pediatric and Young Adult Patients with;Relapsed/Refractory Solid Tumors
Paris
ISABELLE AERTS
VADS
NBTXR3-102
A Phase I Dose-Escalation Study of NBTXR3 Activated by Intensity Modulated Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Paris
CHRISTOPHE LE TOURNEAU
Gynécologie - Ovaires
TG4050.01
A phase I trial evaluating a mutanome-directed immunotherapy in patients with high grade serous carcinoma (HGSC) of the ovary, fallopian tube or peritoneum who experience an asymptomatic relapse
Paris
CHRISTOPHE LE TOURNEAU
VADS
TG4050.02
A randomized phase I trial in patients with newly-diagnosed, locoregionally advanced, HPV-negative, squamous cell carcinoma of the head and neck (SCCHN);evaluating a mutanome-directed immunotherapy;initiated at completion of primary treatment or at time of recurrence
Paris
CHRISTOPHE LE TOURNEAU